Rhombus

Rhombus Therapeutics is a biotechnology company focused on developing novel small molecule therapeutics for the treatment of autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to identify and modulate challenging protein-protein interactions that were previously considered undruggable. By targeting these specific molecular pathways, Rhombus aims to create highly selective therapies with improved safety and efficacy profiles compared to current standards of care. Founded by Third Rock Ventures, the company operates at the intersection of advanced structural biology and computational chemistry to advance its internal pipeline of immunology programs.